

# Our performance

Performance data helps us evaluate the quality of patient care provided at Gundersen Center for Cancer & Blood Disorders and Norma J. Vinger Center for Breast Care.

The Cancer Program Practice Profile Report (CP3R) is a reporting tool we use to promote continuous practice improvement locally and to compare our care with cancer centers across the nation. It is designed to help us identify problems in practice and delivery, and

to work collaboratively with Commission on Cancer (CoC)-accredited cancer programs toward continual improvement.

The estimated performance rates for breast, colon and lung cancer (shown below) provide an indication of Gundersen Health System's performance according to recognized standards of care from 2012–2016. The data comes from the National Cancer Data Base.

## Gundersen Health System Cancer Program Practice Profile Report (CP3R)

Measure Definition	Target	2012	2013	2014	2015	2016
<b>Breast</b>						
Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage IB-III hormone receptor positive breast cancer (Accountability)	90.00	100.00	98.80	97.10	100.00	97.10
Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer (Quality Improvement)	80.00	91.00	93.60	95.30	90.20	98.00
Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with $\geq 4$ positive regional lymph nodes (Accountability)	90.00	100.00	88.90	100.00	100.00	100.00
Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0, or stage IB - III hormone receptor negative breast cancer (Accountability)	Not Applicable	100.00	100.00	100.00	100.00	100.00
<b>Colon</b>						
<b>Select measures</b>	<b>Target</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>
At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (Quality Improvement)	85.00	94.40	96.70	96.60	97.30	100.00
<b>Lung</b>						
<b>Select measures</b>	<b>Target</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>
Surgery is not the first course of treatment for cN2, M0 lung cases (Quality Improvement)	85.00	100.00	100.00	100.00	92.90	100.00